معرفی
Professor David Allsup is a Professor of Haematology at the Hull York Medical School, University of Hull, and serves as an Honorary Consultant Haematologist at Hull University Teaching Hospitals. He holds significant clinical responsibilities as the local haemophilia director with additional expertise in inherited and acquired platelet disorders, and serves as the local lead for chronic lymphocytic leukaemia (CLL).
His educational background includes a BSc and MB ChB from the University of Leicester (1986-1992), followed by a PhD from the University of Liverpool (2000-2004) with research focused on "B-cell receptor signalling in chronic lymphocytic leukaemia." He is a Fellow and Senior Fellow of the Higher Education Academy (FHEA, SFHEA).
Professor Allsup's research primarily centers on platelet disorders, the biology of chronic lymphocytic leukaemia, novel therapeutic approaches for haematological malignancies, clinical trials, patient pathways, and infection risk associated with blood cancers. His work bridges clinical practice with translational research, particularly in developing new treatment strategies for haematological conditions.
Analysis of his recent publications reveals a strong focus on CLL treatment advancements, particularly regarding BTK inhibitors like ibrutinib and acalabrutinib, measurable residual disease-guided therapy, and the molecular mechanisms of drug resistance. His research also extends to antifungal stewardship in acute leukemia patients and platelet disorder investigations using nanotechnology approaches.
- Fellow of the Higher Education Academy (FHEA)
- Senior Fellow of the Higher Education Academy (SFHEA)
As an educator, Professor Allsup teaches undergraduate medical students in phase II, provides haematology postgraduate teaching, and serves as an educational and clinical supervisor for medical and haematology trainees. He externally examines PhDs and supervises postgraduate students at PhD and Masters levels. His research leadership includes directing 14 significant research projects, such as the Biomarker Driven Antifungal Stewardship (BioDriveAFS) trial, studies on endometriosis and bleeding disorders, and multiple clinical trials focused on CLL treatment strategies.
His laboratory and research group work within the Centre for Biomedicine at the University of Hull, focusing on translational research that connects basic science discoveries with clinical applications in haematology. Current work emphasizes improving patient outcomes through personalized treatment approaches and better understanding of disease mechanisms in blood disorders.
